Pediatrix Medical Group (MD) Reported Higher Earnings, Is The Stock Fully Valued?
What triggered the latest move in Pediatrix Medical Group stock
Pediatrix Medical Group (MD) is back in focus after reporting second quarter and first half 2026 results that showed higher sales, net income, and earnings per share from continuing operations compared with a year earlier.
See our latest analysis for Pediatrix Medical Group.
Pediatrix Medical Group's recent earnings release and addition to the Russell 2000 Defensive indexes come after a steady run, with a 90 day share price return of 10.14%, year to date share price return of 22.50%, and a 1 year total shareholder return of 84.70%. However, the 5 year total shareholder return is still down 20.10%.
If strong recent results have you reassessing healthcare exposure, this can be a good moment to scan for other opportunities in the space using our healthcare focused stock list, including 43 healthcare AI stocks
Recent gains in Pediatrix Medical Group stock sit between steady earnings progress and a shift in how investors view its role in defensive healthcare. The next step is to see what the current valuation actually reflects.
Most Popular Narrative: 13% Overvalued
The most followed narrative for Pediatrix Medical Group sees fair value at $23.17 using a 7.13% discount rate, compared with the last close of $26.08.
Analysts are assuming Pediatrix Medical Group's revenue will grow by 3.0% annually over the next 3 years. Analysts assume that profit margins will shrink from 9.0% today to 8.0% in 3 years time.
If you want to see what sits behind that lower margin assumption, the narrative leans heavily on measured revenue growth and a tighter earnings multiple. The full set of projections is where the story gets interesting.
Result: Fair Value of $23.17 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Pediatrix Medical Group still faces pressure from portfolio restructuring, which has reduced consolidated revenue, and from rising salary costs that could weigh on margins if not carefully managed.
Find out about the key risks to this Pediatrix Medical Group narrative.
Another View on Pediatrix Medical Group's Valuation
The earlier narrative framed Pediatrix Medical Group as 13% overvalued at $26.08 versus a fair value of $23.17. Looking at the current P/E of 11.8x against peers at 20.5x and a fair ratio of 19.2x suggests the stock sits at a clear discount, which could point to either mispricing or higher perceived risk. Which explanation appears more convincing to you?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals around Pediatrix Medical Group's valuation, sentiment is not straightforward. Consider acting promptly and testing the numbers against your own view. To keep both the potential upside and the key concerns in focus, review the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Pediatrix Medical Group?
If Pediatrix Medical Group has sharpened your focus on opportunities, do not stop here. Broaden your watchlist now so you are not playing catch up later.
- Target resilient potential by reviewing companies screened for lower overall risk profiles through the 83 resilient stocks with low risk scores.
- Spot possible value opportunities early by scanning the 51 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
- Strengthen portfolio foundations by checking stocks in the solid balance sheet and fundamentals stocks screener (48 results) that pair financial stability with underlying business quality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com